Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years old, of any gender
• People who have been confirmed through a biopsy or cell sample to have pancreatic cancer that started in the ductal lining of the pancreas, and whose cancer has spread to other parts of the body (stage IV)
• People who have not yet received any cancer treatment, such as chemotherapy, targeted therapy, or immunotherapy
• People who have at least one measurable area of cancer that can be tracked during the trial (as determined by standard imaging guidelines), which has not been treated with radiation — or if it has, there is confirmed evidence the cancer has grown there since
• People with a general health/activity level rated as 0 or 1 on a standard medical scale, meaning they are either fully active or can carry out light work (confirm with trial site)
• People whose doctors estimate they are likely to live for at least 3 more months
• People whose blood test results show that key organs — including the blood, liver, kidneys, and heart — are functioning well enough to meet specific levels set by the trial (confirm with trial site for exact values)
• People whose heart is pumping at least 50% of its capacity, as measured by an ultrasound
• People whose heart rhythm is within an acceptable range on an electrocardiogram (ECG)
• Women who could become pregnant must have a negative blood pregnancy test within 3 days before joining, and must agree to use reliable contraception during the trial and for 6 months after finishing treatment
• Men must either have had a surgical sterilisation procedure or agree to use reliable contraception during the trial and for 3 months after finishing treatment
• People who are willing to participate and have signed a consent form agreeing to take part

Who may not be able to join:

• People whose pancreatic cancer did not start in the ductal lining — for example, those with pancreatic neuroendocrine carcinoma, pancreatoblastoma, or solid-pseudopapillary tumours
• People whose cancer has spread to the brain or central nervous system
• People with serious digestive problems such as gastrointestinal bleeding, blockage, significant inflammation, or more than mild diarrhoea
• People who have a significant build-up of fluid in body cavities such as the chest, that cannot be kept stable without ongoing drainage — within 2 weeks before joining
• People who have fluid in the abdomen (ascites) causing symptoms that require draining, or who have had it drained in the past 3 months (small amounts shown only on imaging with no symptoms may still be eligible — confirm with trial site)
• People who currently have, or have previously had, a serious lung condition such as interstitial lung disease, pulmonary fibrosis, drug-related lung inflammation, or active tuberculosis
• People who have an active autoimmune disease, or a history of one that may return — such as autoimmune hepatitis, vasculitis, or inflammatory bowel disease (some conditions that are well-controlled, such as thyroid conditions managed with hormone replacement, type 1 diabetes managed with insulin, or childhood asthma that has fully resolved, may still be eligible — confirm with trial site)
• People with severe nerve damage in their hands or feet (peripheral neuropathy rated grade 3 or higher on a standard medical scale)
• People who have had a serious infection — such as severe pneumonia or a bloodstream infection — within 4 weeks before joining, or who needed intravenous antibiotics for an infection within 2 weeks before joining
• People who have received immune-suppressing steroid medications at doses above a certain level within 2 weeks before joining
• People who have had radiation therapy within 2 weeks before joining
• People who have had major surgery, such as open chest or abdominal surgery, within 4 weeks before joining
• People who have received another experimental treatment as part of a different clinical trial within 4 weeks before joining
• People with abnormal blood clotting, a tendency to bleed, or who are currently receiving thrombolytic or anticoagulant (blood-thinning) therapy (low-dose aspirin and certain low-dose blood thinners may be allowed — confirm with trial site)
• People with poorly controlled heart conditions, including significant heart failure, unstable chest pain (angina), a heart attack within the past 6 months, or serious heart rhythm problems requiring treatment
• People who have had another type of cancer in the past 5 years, except for certain treated skin cancers or cervical carcinoma in situ
• People who are known to be allergic to any of the study drugs: a PD-L1 inhibitor, albumin-bound paclitaxel, gemcitabine, or decitabine
• People known to have HIV/AIDS, a positive HIV test, or an active syphilis infection
• People with a confirmed history of a significant neurological or psychiatric condition, such as epilepsy or dementia
• People who, in the opinion of the trial doctor, have other circumstances that may make it unsafe or impractical for them to complete the trial

Important: Always verify eligibility with the trial site directly before applying.